Search - tctmd.com

Displaying 21 - 40 of 51

Sort: Relevancy | Date

News Daily News

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

L.A. McKeown

August 20, 2021

News Opinion CV Team Dispatch

July/August 2021 News Roundup

L.A. McKeown

August 01, 2021

News Daily News

Making the Case for Sex-Specific CVD Guidelines

L.A. McKeown

July 08, 2021

News Daily News

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Todd Neale

July 06, 2021

News Conference News ACC 2021

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Michael O'Riordan

May 25, 2021

News Conference News ACC 2021

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Yael L. Maxwell

May 16, 2021

News Conference News AHA 2020

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

Michael O'Riordan

November 17, 2020

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2020

Shelley Wood

October 01, 2020

News Daily News

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

L.A. McKeown

June 08, 2020

News Daily News

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

L.A. McKeown

October 23, 2019

News Daily News

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

Michael O'Riordan

October 18, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for September 2019

Shelley Wood

October 01, 2019

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Shelley Wood

August 22, 2019

News Daily News

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

Marcus A. Banks

July 12, 2019

News Daily News

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

L.A. McKeown

March 21, 2019

News Daily News

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

Todd Neale

March 04, 2019

News Features

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

Michael O'Riordan

February 01, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for January 2019

Caitlin E. Cox

January 31, 2019

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for December 2018

Caitlin E. Cox

January 01, 2019

News Features

Top News in Heart Failure: 2018

Shelley Wood

December 28, 2018

Advertisement

Uptick in ‘Implausible’ Cancers Reported After ARB Recalls

July/August 2021 News Roundup

Making the Case for Sex-Specific CVD Guidelines

Empagliflozin Succeeds in HFpEF: EMPEROR-Preserved Top-line Results

Sotagliflozin Beneficial Across a Range of Patients, Including HFpEF

Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF

Sotagliflozin Scores Wins in SCORED and SOLOIST-WHF Trials

TCTMD’s Top 10 Most Popular Stories for September 2020

Risk of Dying Doubled in Wuhan COVID-19 Patients With Hypertension

Nighttime Hypertension Drug Dosing May Reduce Risk of CVD

ARB Use Linked to Suicide in New Study, but Is the Finding Real?

TCTMD’s Top 10 Most Popular Stories for September 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

Sudden, ‘Biologically Implausible’ Rise in Valsartan-Linked Neoplasms After 2018 Recall

FDA: Some Tainted Losartan Must Remain on US Market to Maintain Adequate Access for Patients

FDA Provides Update on Tainted ARB Investigation, With New Impurity Found

Hopes Fade for a CV Indication for Canakinumab: What’s Next for the Inflammatory Hypothesis?

TCTMD’s Top 10 Most Popular Stories for January 2019

TCTMD’s Top 10 Most Popular Stories for December 2018

Top News in Heart Failure: 2018

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content